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Abstract The risk of serious bacterial infectious events
(SIEs) after an RTX course used in severe and refractory cases
of systemic autoimmune diseases (SAID) is well known. Risk
factors for SIEs merit investigation. For this case–control
study, data were collected in a single centre of internal med-
icine and included all patients who received rituximab (RTX)
for SAID between 2005 and 2011 (rheumatoid arthritis was
excluded). Sixty-nine patients with SAID received a total of
87 RTX courses. Thirteen SIEs were reported in 12 patients
leading to death in 5 patients. Patients with a history of SIE
were significantly older (63.6±18.8 vs 48.8±16.7; p=
0.0091), suffered most frequently of diabetes mellitus
(33.3 % vs 5.3 %, p=0.015), had a lower CD19 count (1.0±
1.2/mm3 vs 3.9±7.2/mm3) and had most frequently a predni-
sone dose >15 mg/day (91.7 % vs 47.7 %) at the start of the
first RTX course. The SIE rate was 18.7 per 100 patient-years.
At the initiation of the RTX course, risk factors for SIEs were
lower IgG levels (OR=0.87, 95%CI=0.77–0.99, p=0.03),
lower CD19 count (OR=0.85, 95%CI=0.73–1.00) and creat-
inine clearance≤45 ml/min (OR=7.78, 95%CI=1.36–44.38,
p=0.002). Conversely history of pneumococcal vaccination
significantly decreased the risk of SIEs (OR=0.11, 95%CI=
0.03–0.41, p=0.0009). Concomitant treatment with predni-
sone at a dose >15 mg/day significantly increased the SIE risk
(OR=8.07, 95%CI=1.94–33.59, p=0.0004). SIEs are fre-
quent in SAID treated with RTX, particularly in patients
receiving high-dose corticosteroids, in patients with renal
insufficiency and in patients with low IgG levels or a low
CD19 count.
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Introduction
Biologic agents are regularly used for the management of
systemic autoimmune diseases (SAID) refractory to conven-
tional therapy or dependent of high corticosteroid doses [1].
Rituximab (RTX) is a monoclonal antibody that targets
CD20+ B cells. The CD20 antigen is restricted to B lympho-
cytes at the pre-B cell stage but is not present in mature plasma
cells or stem cells [2]. Peripheral B cell depletion lasts for an
average of 6–9 months and sometimes longer [3]. B cells that
return from the bone marrow to the peripheral blood after
depletion are immature or naive, rather than memory B cells
[4]. This delayed development of memory cells appears to
persist for several years after RTX treatment [5].
Despite two negative randomized trials in systemic lupus
erythematosus (SLE) [6, 7], RTX is frequently used in severe
and refractory SLE. The positive results of two randomized
clinical trials in antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis [8, 9] will increase their use in this
indication, sometimes as a first line therapy. The increased
risk of infection due to RTX use in SAID has already been
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reported upon [10, 11]. The risk of serious infectious events
(SIEs) remains several months after an RTX course, the ma-
jority within the 6 months of the RTX infusion [12]. The main
goal of the study was to identify the risk factors for the SIEs
occurring within 12 months after the first RTX administration
in any course of RTX.
Materials and methods
Method
The primary objective of our study was to evaluate the risk
factors of SIEs in RTX treated patients. This is a case–control
study. Cases for analysis were defined as “RTX courses with
occurrence of SIEs” and controls as “RTX courses without
SIEs”. Data were collected in a single centre of internal med-
icine (National Centre for Rare Systemic Auto-immune
Diseases, Lille, France). All patients who received off-label
RTX for SAID between 2005 and 2011 were included in the
study. Due to the individual and nominative dispensation of this
drug, the central pharmaceutical department was able to for-
ward an exhaustive list of all the patients treated in our depart-
ment. There were no exclusion criteria; all patients were taken
into account. A course of RTX was defined as IV infusions of
either 2×1,000 mg given 2 weeks apart or 4×375 mg/m2
given 4 weeks apart. At each RTX infusion, 100-mg
methylprednisolone was systematically administered in-
travenously to prevent perfusion reactions. SIEs were
defined as any infection which led to hospitalization
and/or death and/or required treatment with intravenous
antibiotic/antiviral drugs. Nosocomial infections were
defined as localized or systemic conditions that resulted
from adverse reactions to the presence of (an) infectious
agent(s) or its toxin(s) and that were not present or incubating
at the time of hospital admission. For most bacterial nosoco-
mial infections, this means that the infection usually becomes
evident 48 h or more after admission [13]. History of hospi-
talization of at least 48 h within the previous 90 days [14] was
also collected to individualize a subset of patients correspond-
ing to health care-associated infections [15].
This research was authorized by the French competent
authority dealing with research on human biological samples
namely the French Ministry of Research. The authorization
number is DC 2008 642. To issue such authorization, the
Ministry of Research has sought the advice of an independent
ethics committee, namely the “Comité de Protection des
Personnes”. The committee voted positively on the quality
of information provided to patients and the obtainment of
consent for the intended use in research. Therefore, we attest
that this study was conducted in accordance with French
regulations concerning human research, and no breach to
clinical research rules was observed.
Statistics
SIEs were right censored at 12 months after the first perfusion
of RTX for each treatment course. The influence of patient’s
characteristics at the start of an RTX course was estimated by
logistic regression models. Some patients underwent several
courses of RTX, and, as analysis had focus on each RTX
course and not on each patient, these RTX courses for a same
patient could not be assumed to be independent. Therefore,
the analysis was adjusted for clustered data (procedure
SURVEYLOGISTIC). Results are expressed as odds ratios
with their two-sided 95% confidence intervals. Analyses were
conducted using the SAS 9.1.3 statistical software (SAS
Institute, Cary, NC, USA).
Results
Patients
Sixty-nine patients entered the study, and none were lost to
follow-up. Among them, 55 patients received one course of
treatment, 10 received two courses and 4 received three
courses. A total of 87 RTX courses involving 69 patients were
analysed. Fifty-six patients (81.2 %) were female; the mean
age was 51.4±18.1 years. Patients were suffering from SLE (n
=22), Sjögren’s syndrome-associated vasculitis (n=14),
ANCA-associated vasculitis (n=9), idiopathic mixed
cryoglobulinaemia vasculitis (n=10), haematologic auto-
immune disorders (autoimmune haemolytic anaemia/
id iopa th ic th rombocytopen ic purpura /acqui red
haemophilia with anti-factor VIII antibodies) (n=12),
myositis (n=3) or catastrophic antiphospholipid syn-
drome (n=1). RTX was mostly given to patients con-
sidered to be refractory to conventional therapy includ-
ing corticosteroids and at least one immunosuppressive
drug (n=64, 92.8 %) or to patients who were dependent
on a high dose of corticosteroid (i.e. prednisone 20 mg
or more per day) for the purpose of corticosteroid
sparing (n=5, 7.2 %). Forty-three (62.3 %) patients had
received pneumococcal vaccination (40 before and 3 after the
first RTX course). Twelve patients experienced at least one
SIE during or after an RTX course; one patient experienced
two SIEs after the first and the third cure, respectively.
Characteristics of patients with or without SIE before
the first cure are given in Table 1. Comparisons in-
volved 12 patients with at least one SIE and 57 patients
who never had SIE. Patients with a history of SIE were
significantly older, suffered most frequently of diabetes
mellitus, had a lower CD19 count and had most frequently a
prednisone dose >15 mg/day at the start of the first
RTX course.
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RTX courses
Mean number of RTX perfusions was 2.9±1.1 perfusions per
RTX course. In patients who received several RTX courses,
the mean delay between two courses was 36.6±19.2 months.
Immediate tolerability was good in all patients. Side
effects were mild and common: diarrhoea (n=2), head-
aches (n=3), hyperthermia (n=3), asthenia (n=3), flu-
like symptoms (n=2) and mild upper respiratory tract
infections (n=11). One patient developed a serum sick-
ness with arthralgia, cutaneous rash and hyperthermia
8 days after the end of the second course with a rapid spon-
taneous favourable evolution despite the first course having
been well tolerated. During RTX courses, concomitant treat-
ments were immunosuppressive drugs (n=26, 29.9 %) and
prednisone at a dose >15 mg/day (n=41, 47.1 %). These
treatments were pursued for a further 6 months after the end
of the RTX course.
Laboratory monitoring
Ig levels, CD4 lymphocyte count and CD19 lymphocyte
count were monitored. Due to the observational nature of the
study, data were not collected at regular intervals. Before the
first RTX infusion for each cure, the mean IgG level
was 9.9±6.9 g/l (n=51), and lymphocyte counts were
1,267±976/mm3 with 627±474 CD4/mm3 and 3.4±6.4
CD19/mm3. During the 6 following months, the mean
IgG level decreased to a nadir of 8.7±4.8 g/mm3 (n=
56) compared to IgA or IgM which both remained
virtually unchanged. Sixteen out of 42 patients with
documented IgG values experienced an IgG level below
6 g/l, and ten had a nadir below 5 g/l. Post course CD19
counts were documented in 59 patients, and 31 (52.5 %) had
no CD19 (i.e. a count equal to 0/mm3) after the RTX course.
CD4 count decreased from 627±474/mm3 to a nadir of 469±
384/mm3. In 14 out of 58 documented patients, the nadir was
<200/mm3.
Severe infections
Twelve patients experienced at least one SIE during or after an
RTX course (17.4 % of patients). Thirteen SIEs were reported
(14.9 % of RTX courses). All were bacterial or suspected
bacterial infections. Within 6 months following the first infu-
sion of a course, we observed 11 SIEs in 11 patients (12.6% of
RTX courses). Two other SIEs (one pneumonia and one
sinusitis that occurred, respectively, 208 days and 345 days
after the first RTX infusion of the course) occurred more than
6 months after the RTX course. Baseline characteristics of
cases and controls at beginning of the RTX course are given in
Table 2. Severe infection rate was 18.7 per 100 patient-years.
Individual data of SIEs are provided in Table 3. However, if
data are analysed as a percentage of the numbers of patients in
each group, some particularities seem to emerge: 3 lupus
patients out of 22 developed an SIE (13 %) in contrast to 2
Table 1 Characteristics of pa-
tients with or without history of
severe infection events
amethotrexate (N=9), azathio-
prine (N=8), leflunomide (N=4),
mycophenolate mofetil (N=4),
cyclophosphamide (N=1)
Status of the patients at the start of the first
rituximab course
Patients with history of
SIEs (n=12)
Patients without history of
SIEs (n=57)
p
Mean age+/−SD 63.6±18.8 48.8±16.7 0.0091
Gender: male/female 3 (25 %)/9 10 (17.5 %)/47 0.68
SLE 3 (25 %) 19 (33.3 %) 0.74
Sjögren 1 (8.3 %) 13 (22.8 %) 0.44
ANCAvasculitis 2 (16.7) 7 (12.3 %) 0.65
Idiopathic cryoglobulinaemia vasculitis 4 (33.3 %) 6 (10.5 %) 0.06
Haematologic autoimmune disorders 4 (33.3 %) 8 (14.0 %) 0.20
Diabetes mellitus 4 (33.3 %) 3 (5.3 %) 0.015
Gammaglobulin level (g/l) 7.9±5.4 11.4±5.8 0.18
IgG level (g/l) 7.5±4.1 11.9±7.3 0.20
Lymphocyte count (100/mm3) 656.5±597.1 1,353.1±1,057.5 0.20
CD19 count (/mm3) 1.0±1.2 3.9±7.2 0.03
CD4 count (100/mm3) 550.1±551.4 605.9±465.6 0.78
Creatinine clearance (ml/min) 75.9±41.4 85.4±31.2 0.37
Creatinine clearance ≤45 ml/min 4 (33.3 %) 3 (5.3 %) 0.15
Creatinine clearance ≤60 ml/min 5 (41.7 %) 13 (22.8 %) 0.28
Concomitant immunosuppressive drug a 2 (16.7 %) 20 (35.1 %) 0.31
Previous immunosuppressive drug a 3 (25 %) 23 (40.4 %) 0.51
Prednisone >15 mg/day 11 (91.7 %) 27 (47.4 %) 0.005
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out of 9 ANCA vasculitis (22 %), 4 out of 12 with a
haematologic autoimmune disorder (33 %) and 4 out of 10
with idiopathic cryoglobulinaemia vasculitis (40 %). Over the
12-month period following the start of RTX course, five
patients died from infections (5/12), and one died due to
another cause (Paget’s disease of the breast at month 6).
None of those who died from infection had received pneumo-
coccal vaccination, and all had received prednisone at a dose
>15 mg/day concomitant with RTX. Four of the five infected
deceased patients were older than 70 years old.
Streptococcus pneumoniaewas identified in 3/13 SIEs, one
febrile neutropenia and sepsis that occurred within 1 month
after the first dose of RTX course and one sinusitis and one
pneumonia having occurred, respectively, 208 and 345 days
after the beginning of the RTX course. For these two patients,
the relationship with RTX was considered as probable as IgG
levels were <6 g/l (respectively, 5.9 g/l and 1.79 g/l) at the time
of infection. Six out of the 11 SIEs observed during the
6 months following the RTX course were nosocomial infec-
tions (occurring during a hospitalization period or during the 2
following days).
Factors associated with SIEs occurring within 12 months
following RTX courses
Risk factors for SIEs were investigated by logistic regression
models for clustered data (Table 3). At the initiation of the
RTX course, the risk factors for SIEs were lower IgG levels
(OR=0.87, 95%CI=0.77–0.99, p=0.03), lower CD19 count
(OR=0.85, 95%CI=0.73–1.00) and creatinine clearance
≤45 ml/min (OR=7.78 95%CI=1.36–44.38, p=0.002).
Conversely, history of pneumococcal vaccination signif-
icantly decreased the risk of SIEs (OR=0.11, 95%CI=
0.03–0.41, p=0.0009). Concomitant treatment with pred-
nisone at a dose >15 mg/day significantly increased the
SIE risk (OR=8.07, 95%CI=1.94–33.59, p=0.0004). We
did not find a cutoff point either for IgG level (IgG
<6 g/l: OR=2.19, 95%CI=0.52–9.22, p=0.28) nor for
gamma globulins level (gamma globulins <6 g/l: OR=
1.77 95%CI=0.55–5.74, p=0.34). Odds ratio for age at
the time of RTX course did not reach statistical signif-
icance (p=0.08) most probably partly due to the small
number of events.
Table 2 Individual data of patients with severe infections
Sex/
age
Diagnosis CT and IS at time
of SIE
PV Infection/time from the
RTX course
Pathogen Outcome
1 F/45 V/SG P>15 mg/day Y Bronchitis/month 2 – Favourable




3 F/49 SLE P<15 mg/day Y Pneumonia/month 6 – Favourable
4 F/73 SLE P<15 mg/day N Hand cellulitis/month 3 Staphylococcus aureus methy-R Favourable
5 F/75 AH P>15 mg/day N Pneumonia/month 1 Pseudomonas aeruginosa nombreux
Pneumocystis + Candida
albicans + Enterobacter cloacae
(nosocomial infection)
Death related to infection
6 F/75 V/CG P>15 mg/day N Suspected endocarditis/
month 1
– Death related to acute renal failure
and infection
7 M/66 AH P>15 mg/day Y Septicemia/month 2 Enterococcus faecalis (possible
nosocomial infection)
Favourable
8 F/21 SLE IS+P>15 mg/day N Pneumonia/month 1 –
(possible nosocomial infection)
Favourable










Death related to infection





surgery in a septic context
12 F/47 SLE P>15 mg/day N Sinusitis/month 11 Streptococcus pneumoniae PSDP +
Haemophilus influenzae
Favourable
13 M/70 W P>15 mg/day N Pneumonia/month 10 Streptococcus pneumoniae +
Haemophilus influenzae
Favourable
V vasculitis, SG Sjögren syndrome, CG cryoglobulinaemia, SLE systemic lupus erythematosus, AH acquired haemophilia,WWegener’s disease, AIHA
autoimmune haemolytic anaemia, RTX rituximab, PV pneumococcal vaccination, D death, Y yes, N no, CT concomitant treatments, P prednisone, IS
immunosuppressive drug
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Discussion
The main goal of this case–control study was to investigate
risk factors for SIE in patients who received off-label RTX for
SAID. Within 12 months following the first infusion of each
RTX course, we observed 13 SIEs in 12 patients most of them
occurring within the 2 months after the first perfusion of RTX.
We found that patients with a history of SIE were significantly
older, suffered most frequently of diabetes mellitus, had a
lower CD19 count and had most frequently a prednisone dose
>5 mg/day at the start of the first RTX course. Moreover, a
lower level in gamma globulins, a lower CD19 count and
renal failure (creatinine clearance ≤45 ml/min) at initiation of
an RTX course increased the risk of SIE. Conversely, the SIE
risk was lower in patients having been vaccinated against
S. pneumonia. A concomitant treatment with prednisone at a
dose >15 mg/day was associated with a higher risk of SIEs.
Severe infectious event rate
SAIDs are at high risk of SIEs with a rate of 18.7 SIEs/100
patient-years. Other studies conducted in rheumatoid arthritis
(RA) patients and SLE patients have found lower rates
(around 4 to 6 SIEs/100 patient-years) [16, 17]. Diaz
Lagarez et al. [10], however, found an 11.2 SIEs/100
patient-years SIE rate in patients suffering from SAID with a
22.6 SIEs/100 patient-years SIE rate in patients treated with
more than two RTX courses. The risk of SIEs was not
increased by addition of RTX to methotrexate (MTX) when
compared to MTX alone. In the randomized EXPLORER
study (phase II/III extra renal SLE evaluation of RTX), the
SIE rate was lower in the RTX group compared to the placebo
group (9.5% and 17%, respectively) [7]. Another randomized
study [9] compared RTX and cyclophosphamide in patients
with ANCA-associated renal vasculitis. There were 19 SIEs in
12 of the 33 patients treated by RTX (36 %) and 7 SIEs in 3 of
the 11 patients (27 %) treated with cyclophosphamide. The
difference was not significant between the two groups. Three
patients died from infection in the RTX group versus one in
the cyclophosphamide group. Van Vollenhoven et al. [18]
studied the influence of the number of courses on the infection
rate in RA patients treated with RTX and MTX. It emerged
that neither the number of courses nor the total exposure time
to RTX had any effect on the risk of SIEs. In our study,
interestingly, patients with SLE seem at far less risk of devel-
oping SIEs. Indeed, the fact that the average age of patients
with a history of infections is 63 years supports the view that
SLE seems to be relatively at low risk for infection (given the
fact that most lupus patients are much younger).
Pathogen
No viral infection was observed in this cohort. We highlighted
that, in 11 patients who had an SIE during the 6 months
following the course, 2 had community pathogens, and 4 other
patients had hospital-related pathogens. Six SIEs oc-
curred in patients with a past history of an at least
48-h hospitalization within the 90 days before the SIE,
suggesting that the SIE could be nosocomial. Similarly,
Gottenberg et al. found pathogens frequently identified as
Table 3 Risk factors of baseline
characteristics regarding the risk
of severe bacterial infection (uni-
variate analysis)
OR odds ratio, RTX rituximab
a 13 cases and 74 controls; OR
provided by univariate regression
models
ORa 95%CI P
Age (years) 1.05 [0.99–1.10] 0.08
Female sex 0.58 [0.13–2.61] 0.48
Treatment with IVIg within 3 months prior to RTX course 1.74 [0.31–9.75] 0.53
Immunosuppressive drugs within 6 months before RTX course 0.82 [0.24–2.84] 0.75
Concomitant treatment with immunosuppressive drugs 0.38 [0.07–1.97] 0.25
High-dose IV methylprednisolone within 1 month before RTX course 2.17 [0.54–8.71] 0.28
Concomitant treatment with prednisone >15 mg/day 8.07 [1.94–33.59] 0.004
Statin use 1.92 [0.42–8.76] 0.40
Creatinine clearance >60 ml/min 0.51 [0.14–1.85] 0.31
Creatinine clearance ≤60 ml/min 1.94 [0.54–7.00] 0.31
Creatinine clearance ≤45 ml/min 7.78 [1.36–44.38] 0.02
Hospitalisation >48 h within 180 days before RTX course 1.94 [0.55–6.87] 0.30
Pneumococcal vaccination 0.11 [0.03–0.41] 0.0009
Nadir of gammaglobulin rate during the 6 months after RTX course (g/l) 0.67 [0.52–0.86] 0.002
IgG level at start of RTX course (g/l) 0.87 [0.77–0.99] 0.03
Lymphocyte count at start of RTX course (100/mm3) 0.83 [0.64–1.08] 0.17
CD19 count at start of RTX course (/mm3) 0.85 [0.73–1.00] 0.05
CD4 count at start of RTX course (100/mm3) 0.96 [0.76–1.21 0.71
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possibly nosocomial and included Pseudomonas aeruginosa,
Escherichia coli, and Staphylococcus aureus [17]. Thus, there
is an increased risk of nosocomial infection which calls for
caution in the use of RTX in the context of a previous prolonged
hospitalization.
Pneumococcal vaccination
Of the patients who developed SIEs, 72.7 % had not received
pneumococcal vaccine before or during the RTX course ver-
sus 28.9 % of the patients who did not develop SIEs. In the
subgroup of patients who had not received pneumococcal
vaccine before the RTX course, one had severe pneumococcal
sepsis and died, and two others had documented pneumococ-
cal disease, albeit after the 6-month period following the RTX
course. In the subgroup of vaccinated patients, one had re-
ceived a pneumococcal vaccination 8 months after the first
course (therefore, 3 months before a pneumococcal infection
(patient 12)). The lymphocytic depletion was still complete at
the time of the vaccination (CD19 number=0/mm3), probably
explaining the lack of efficacy of the vaccination. This high-
lights the importance of pneumococcal vaccination before the
first RTX course (at least 3 to 4 weeks when possible) as
recommended [19] and also the need to update all other non-
live attenuated vaccines. The high number of pneumococcal
infections has modified our practice. We now recommend
pneumococcal vaccination in all SAID patients 3 to 4 weeks
before the first course of RTX, when possible. If not, we
propose pneumococcal vaccination simultaneously with the
first RTX administration although it is known that the immune
response against pneumococcal vaccination is reduced in
RTX-treated patients even when the vaccine is administrated
28 weeks after the RTX course [3].
Basal IgG level
Despite a lack of data concerning the IgG levels, it emerged
that a high IgG level at baseline was associated with a lower
risk of SIEs. Common observations showed that IgG’s are the
most important Ig for protective immunity and that patients
who have a low IgG level have an increased risk of SIEs.
However, in the Van Vollenhoven et al. study [18], the effect
of IgG at baseline was not significant. We advise discussion
on the use of IVIg in patients who have an IgG level <5 g/l
before RTX treatment, particularly in patients who have a past
history of severe infection.
Corticosteroid dosage
In 81.8 % of RTX courses with SIEs, the patients were
concomitantly receiving prednisone at a dose >15 mg/day
versus 42.1 % of RTX courses without SIE. In a meta-
analysis focusing on the infectious risk in patients taking
corticosteroids, no SIEs occurred when the prednisone daily
dose was lower than 10 mg [20]. When possible, corticoste-
roids should be used at low doses in association with RTX. In
lupus nephritis for example, it has previously been shown that
remission is possible with immunosuppressive drugs and cor-
ticosteroids at a dose of 10 mg/day [21].
Limitations
The major limitation of the study is its retrospective nature.
Nevertheless, due to the traceability of RTX dispensation, all
SAIDs treated in our department during the 2005–2011 period
were collected, and no patients were lost to follow-up. The
lack of a control group of patients suffering from SAID not
exposed to RTX definitely makes it difficult to attribute the
high rate of SIEs to the RTX use. Due to the multiple aspects of
SAIDs, we cannot rule out that the type of SAIDmay influence
the SIE risk. Multivariate analysis was not possible due to the
small number of events. Finally, due to the low number of
patients involved who were retreated, it is not possible to
evaluate the effect of retreatment on the risk of SIEs.
Conclusions
This study identified four main risk factors associated with an
increased risk of SIEs in SAID patients treated with RTX:
high-dose corticosteroids (>15 mg/day), renal insufficiency
(creatinine clearance ≤45 ml/min), a low IgG level and a low
CD19 count. The high number of pneumococcal infections
has modified our practice. We would recommend pneumo-
coccal vaccination in all SAID patients 3 to 4 weeks prior to
the first course of RTX if possible or simultaneously to the
first RTX course if not possible in case of an emergency
situation. IVIg could be discussed in patients who have an
IgG level <5 g/l, particularly if SIEs occur, though this de-
serves further studies. Last but not least, we recommend,
when possible, to limit the corticosteroid dose below 15 mg/
day or to rapidly decrease the corticosteroid dose below
15 mg/day after induction treatment in SAID treated with
RTX.
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